Literature DB >> 5486295

Acute renal failure due to overdosage of colistin.

J M Brown, D C Dorman, L P Roy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5486295

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  17 in total

1.  Colistin: the phoenix arises.

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

2.  Population pharmacokinetic analysis of colistin in burn patients.

Authors:  Jongtae Lee; Seunghoon Han; Sangil Jeon; Taegon Hong; Wonkeun Song; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Authors:  Sofia K Kasiakou; Argyris Michalopoulos; Elpidoforos S Soteriades; George Samonis; George J Sermaides; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 4.  The rise and spread of mcr plasmid-mediated polymyxin resistance.

Authors:  Sue C Nang; Jian Li; Tony Velkov
Journal:  Crit Rev Microbiol       Date:  2019-05-23       Impact factor: 7.624

5.  The use of intravenous colistin among children in the United States: results from a multicenter, case series.

Authors:  Pranita D Tamma; Jason G Newland; Pia S Pannaraj; Talene A Metjian; Ritu Banerjee; Jeffrey S Gerber; Scott J Weissman; Susan E Beekmann; Philip M Polgreen; Adam L Hersh
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

Review 6.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

7.  Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.

Authors:  Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li
Journal:  ACS Infect Dis       Date:  2015-09-04       Impact factor: 5.084

8.  Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections.

Authors:  M Montero; J P Horcajada; L Sorlí; F Alvarez-Lerma; S Grau; M Riu; M Sala; H Knobel
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

9.  New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.

Authors:  Gauri G Rao; Neang S Ly; Curtis E Haas; Samira Garonzik; Alan Forrest; Jurgen B Bulitta; Pamela A Kelchlin; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 10.  The potential of antimicrobial peptides as biocides.

Authors:  Garry Laverty; Sean P Gorman; Brendan F Gilmore
Journal:  Int J Mol Sci       Date:  2011-10-06       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.